Clinical Trials Directory

Trials / Completed

CompletedNCT01996202

A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Duke University · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

This is a pilot study assessing the safety of the combination of ipilimumab administered concurrently with radiotherapy for patients with locally advanced or unresectable melanoma and patients at high risk for recurrence after resection.

Conditions

Interventions

TypeNameDescription
DRUGIpilumimab
RADIATIONRadiation

Timeline

Start date
2013-11-01
Primary completion
2018-09-01
Completion
2018-09-01
First posted
2013-11-27
Last updated
2019-07-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01996202. Inclusion in this directory is not an endorsement.

A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma (NCT01996202) · Clinical Trials Directory